Point72 Hong Kong LTD Neurocrine Biosciences Inc Transaction History

Point72 Hong Kong LTD

$1.5 Billion
Q1 2025

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $526,816 - $695,586	-6,951 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $313,780 - $410,622	4,331 Added 165.31%	6,951 $652,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $208,683 - $278,296	2,620 New	2,620 $223,000
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $1.54 Million - $1.77 Million	-17,877 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $1.6 Million - $1.83 Million	17,877 New	17,877 $1.74 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $709,929 - $967,975	-8,107 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $545,881 - $680,420	-6,281 Reduced 43.65%	8,107 $777,000
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $1.38 Million - $1.94 Million	14,388 New	14,388 $1.38 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $37,950 - $58,140	-446 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $154,426 - $233,890	-2,056 Reduced 82.17%	446 $39,000
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $47,392 - $64,739	546 Added 27.91%	2,502 $269,000
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $163,951 - $198,534	1,956 New	1,956 $176,000
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $103,592 - $130,881	-1,434 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $99,390 - $131,254	1,434 New	1,434 $126,000
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $33,613 - $61,185	-492 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $48,648 - $61,918	492 New	492 $60,000
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $17,544 - $24,695	-233 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $17,680 - $21,536	233 New	233 $19,000

Others Institutions Holding NBIX

# of Institutions

649

Shares Held

97.1M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.

Account